Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

166930

registered interest
date	01/12/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Animal Experiments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what research his Department has commissioned on the contribution of testing households products and their ingredients on animals to the UK economy; and if he will make a statement.
tabling member constituency	Derby North
tabling member printed	Chris Williamson
uin	216683
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>The Department for Business, Innovation &amp; Skills has not commissioned research on the contribution of testing household products and their ingredients on animals to the UK economy.</p><p> </p><p> </p><p> </p><p>Animal testing in the UK is licensed through the Home Office.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 14:56:42 answering member 4020 label Biography information for George Freeman
tabling member	3976 label Biography information for Chris Williamson

167037

registered interest
date	01/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with (a) NHS England, (b) the Medicines and Healthcare Products Regulatory Agency, (c) patient groups and (d) professional groups about prescribing drugs for licensed and off-label indications.
tabling member constituency	Knowsley
tabling member printed	Mr George Howarth
uin	216568
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>In developing our response to the Off-patent Drugs Bill, we have taken advice from clinicians and officials at NHS England, the National Institute for Health and Care Excellence and the Medicines and Healthcare products Regulatory Agency, and taken account of views expressed by other stakeholder organisations. Officials have also had discussions with Breast Cancer Campaign to understand their concerns around the prescribing of off-patent drugs and the implications for patients.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:07:13 answering member 4020 label Biography information for George Freeman
tabling member	481 label Biography information for Sir George Howarth

167067

registered interest
date	01/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what action he plans to take to ensure that the Cancer Drugs Fund panel consults with expert clinicians when re-evaluating listed treatments for pancreatic cancer.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	216521
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>This is a matter for NHS England. NHS England has advised us that its Cancer Drugs Fund panel includes expert oncologists, haemato-oncologists and oncology pharmacists, as well as patient representatives.</p><p> </p><p><em> </em></p><p> </p><p>Should the panel consider that it requires additional advice on a particular cancer to aid its decision making, it will access this externally as appropriate.</p><p> </p><p> </p><p> </p><p>NHS England’s standard operating procedures for the Fund are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:08:13 answering member 4020 label Biography information for George Freeman
tabling member	1604 label Biography information for Mr Virendra Sharma

167078

registered interest
date	01/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sickle Cell Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what research his Department has published on sickle cell anaemia in the last four years.
tabling member constituency	Wolverhampton South East
tabling member printed	Mr Pat McFadden
uin	216525
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>The NIHR Journals Library comprises a suite of open access journals providing a permanent archive of research funded by the Department’s National Institute for Health Research (NIHR) through five NIHR programmes (Efficacy and Mechanism Evaluation; Health Services and Delivery Research; Health Technology Assessment; Programme Grants for Applied Research; Public Health Research). The NIHR Journals Library is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.journalslibrary.nihr.ac.uk/" target="_blank">http://www.journalslibrary.nihr.ac.uk/</a></p><p> </p><p> </p><p> </p><p>The following reports relating to sickle cell anaemia have been published in the NIHR Journals Library in the last four years:</p><p> </p><p><strong> </strong></p><p> </p><p>- The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation (2012)</p><p> </p><p><strong> </strong></p><p> </p><p>- Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial (2010)</p><p> </p><p><strong> </strong></p><p> </p><p>Across all NIHR funding streams, and across all topic areas including sickle cell anaemia, the Department and the NIHR require that NIHR funded researchers seek to publish their research outputs in a peer-reviewed journal that is compliant with the NIHR policy on open access.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 08/12/2014 15:18:07 answering member 4020 label Biography information for George Freeman
tabling member	1587 label Biography information for Pat McFadden

166746

registered interest
date	28/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ehlers-Danlos Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what research his Department has commissioned on Ehlers-Danlos syndrome.
tabling member constituency	Dudley North
tabling member printed	Ian Austin
uin	216359
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Department has not commissioned any research specifically on Ehlers-Danlos syndrome.</p><p> </p><p> </p><p> </p><p>In March 2014, the Government launched the National Institute for Health Research (NIHR) BioResource to provide a national cohort of healthy volunteers, patients and their relatives who wish to participate in experimental medicine research, and are willing to provide clinical information and samples that will enable them to be recalled for specific studies. The initial focus for the BioResource includes rare diseases. These studies will have the potential to rapidly advance the understanding of disease mechanisms, identify potential drug targets, and improve insight into the therapeutic potential and limitations of existing and emerging therapies.</p><p> </p><p><strong> </strong></p><p> </p><p>A current NIHR BioResource study is investigating the genetic basis of rare inherited connective tissue conditions, mainly the Ehlers-Danlos syndromes and those with overlapping phenotypes, which includes familial thoracic aortic aneurysm/dissection.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 14:17:23 answering member 4020 label Biography information for George Freeman
tabling member	1511 label Biography information for Lord Austin of Dudley

166747

registered interest
date	28/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dupuytren's Contracture
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will implement the National Institute for Health and Care Excellence's latest guidance against the use of collagenase injections for the treatment of Dupuytren's disease.
tabling member constituency	Dudley North
tabling member printed	Ian Austin
uin	216360
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture. We understand that NICE recently consulted with stakeholders on its draft recommendations and expects to issue its final guidance in April 2015.</p><p> </p><p> </p><p> </p><p>In the absence of final guidance from NICE, it is for commissioners to make funding directions based on the available evidence.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 14:15:01 answering member 4020 label Biography information for George Freeman
tabling member	1511 label Biography information for Lord Austin of Dudley

166758

registered interest
date	28/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on the need to recognise levels of unmet need in pancreatic cancer when re-evaluating treatments on the Cancer Drugs Fund.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	216451
answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p> </p><p> </p><p>The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 05/12/2014 14:19:34 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

166766

registered interest
date	28/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to ensure that all treatments for advanced pancreatic cancer shown to be effective are made available to patients on the NHS.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	216468
answer	answer is ministerial correction date of answer 03/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p> </p><p> </p><p>NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p><strong> </strong></p><p> </p><p>We are commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/12/2014 17:17:38 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

166330

registered interest
date	26/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Surgical Mesh Implants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress the working group on transvaginal mesh implants has made; and if he will make a statement.
tabling member constituency	Gosport
tabling member printed	Caroline Dinenage
uin	216204
answer	answer is ministerial correction date of answer 03/12/2014 answer text <p>The working group on vaginal tapes and mesh, chaired by NHS England and including patient representatives, clinical representatives, the Department and the Medicines and Healthcare products Regulatory Agency, has been set up to understand and address the concerns which have been raised about transvaginal mesh implants. The working group is aiming to make recommendations in spring next year.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/12/2014 17:14:22 answering member 4020 label Biography information for George Freeman
tabling member	4008 label Biography information for Dame Caroline Dinenage

166332

registered interest
date	26/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the Chemotherapy Intelligence Unit to publish its national audit of the Cancer Drugs Fund.
tabling member constituency	Walsall South
tabling member printed	Valerie Vaz
uin	216212
answer	answer is ministerial correction date of answer 03/12/2014 answer text <p>We understand that NHS England is working jointly with Public Health England, who manage the Chemotherapy Intelligence Unit, on the Cancer Drugs Fund Audit. <br> <br> NHS England has advised that it is anticipated an analysis from the audit will be published jointly by NHS England and Public Health England early in 2015.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/12/2014 17:09:05 answering member 4020 label Biography information for George Freeman
tabling member	4076 label Biography information for Valerie Vaz